Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease [
1], with a particular aggressive cancer biology and, unfortunately, a poor prognosis for most patients. For this reason, the use of neoadjuvant therapy, either in the form of combined chemotherapy regimens or chemoradiation, has become increasingly used for both resectable, borderline and for locally advanced disease. Use of neoadjuvant therapy in uncontrolled patient series suggest improved survival in selected patients with resectable disease and, may expand the spectrum of patients with locally advanced disease that can be treated surgically after “testing” the disease biology. Thus, as an increased number of patients will receive neoadjuvant treatment before surgical resection for PDAC, it is important to reassess the optimal number of lymph nodes required to accurately stage this disease. …
